These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
422 related articles for article (PubMed ID: 22545118)
1. Inflammation-driven reprogramming of CD4+ Foxp3+ regulatory T cells into pathogenic Th1/Th17 T effectors is abrogated by mTOR inhibition in vivo. Yurchenko E; Shio MT; Huang TC; Da Silva Martins M; Szyf M; Levings MK; Olivier M; Piccirillo CA PLoS One; 2012; 7(4):e35572. PubMed ID: 22545118 [TBL] [Abstract][Full Text] [Related]
2. Conversion of Th17 into IL-17A(neg) regulatory T cells: a novel mechanism in prolonged allograft survival promoted by mesenchymal stem cell-supported minimized immunosuppressive therapy. Obermajer N; Popp FC; Soeder Y; Haarer J; Geissler EK; Schlitt HJ; Dahlke MH J Immunol; 2014 Nov; 193(10):4988-99. PubMed ID: 25305313 [TBL] [Abstract][Full Text] [Related]
3. IL-12 inhibits the TGF-β-dependent T cell developmental programs and skews the TGF-β-induced differentiation into a Th1-like direction. Prochazkova J; Pokorna K; Holan V Immunobiology; 2012 Jan; 217(1):74-82. PubMed ID: 21903294 [TBL] [Abstract][Full Text] [Related]
4. CD4+ Foxp3+ regulatory T cells suppress γδ T-cell effector functions in a model of T-cell-induced mucosal inflammation. Yurchenko E; Levings MK; Piccirillo CA Eur J Immunol; 2011 Dec; 41(12):3455-66. PubMed ID: 21956668 [TBL] [Abstract][Full Text] [Related]
5. Differential Effects of Calcineurin and Mammalian Target of Rapamycin Inhibitors on Alloreactive Th1, Th17, and Regulatory T Cells. Gallon L; Traitanon O; Yu Y; Shi B; Leventhal JR; Miller J; Mas V; L X; Mathew JM Transplantation; 2015 Sep; 99(9):1774-84. PubMed ID: 25905982 [TBL] [Abstract][Full Text] [Related]
6. Increased CD4 Ma YH; Zhang J; Chen X; Xie YF; Pang YH; Liu XJ World J Gastroenterol; 2016 Nov; 22(42):9356-9367. PubMed ID: 27895423 [TBL] [Abstract][Full Text] [Related]
7. mTORC1 couples immune signals and metabolic programming to establish T(reg)-cell function. Zeng H; Yang K; Cloer C; Neale G; Vogel P; Chi H Nature; 2013 Jul; 499(7459):485-90. PubMed ID: 23812589 [TBL] [Abstract][Full Text] [Related]
8. RORγt Promotes Foxp3 Expression by Antagonizing the Effector Program in Colonic Regulatory T Cells. Bhaumik S; Mickael ME; Moran M; Spell M; Basu R J Immunol; 2021 Oct; 207(8):2027-2038. PubMed ID: 34518282 [TBL] [Abstract][Full Text] [Related]
9. In vitro generated Th17 cells support the expansion and phenotypic stability of CD4(+)Foxp3(+) regulatory T cells in vivo. Zhou Q; Hu Y; Howard OM; Oppenheim JJ; Chen X Cytokine; 2014 Jan; 65(1):56-64. PubMed ID: 24080164 [TBL] [Abstract][Full Text] [Related]
10. Impact of protective IL-2 allelic variants on CD4+ Foxp3+ regulatory T cell function in situ and resistance to autoimmune diabetes in NOD mice. Sgouroudis E; Albanese A; Piccirillo CA J Immunol; 2008 Nov; 181(9):6283-92. PubMed ID: 18941219 [TBL] [Abstract][Full Text] [Related]
11. Vitamin A Impairs the Reprogramming of Tregs into IL-17-Producing Cells during Intestinal Inflammation. Tejón G; Manríquez V; De Calisto J; Flores-Santibáñez F; Hidalgo Y; Crisóstomo N; Fernández D; Sauma D; Mora JR; Bono MR; Rosemblatt M Biomed Res Int; 2015; 2015():137893. PubMed ID: 26583087 [TBL] [Abstract][Full Text] [Related]
12. Foxp3(+) T cells expressing RORγt represent a stable regulatory T-cell effector lineage with enhanced suppressive capacity during intestinal inflammation. Yang BH; Hagemann S; Mamareli P; Lauer U; Hoffmann U; Beckstette M; Föhse L; Prinz I; Pezoldt J; Suerbaum S; Sparwasser T; Hamann A; Floess S; Huehn J; Lochner M Mucosal Immunol; 2016 Mar; 9(2):444-57. PubMed ID: 26307665 [TBL] [Abstract][Full Text] [Related]
13. Functional waning of naturally occurring CD4+ regulatory T-cells contributes to the onset of autoimmune diabetes. Tritt M; Sgouroudis E; d'Hennezel E; Albanese A; Piccirillo CA Diabetes; 2008 Jan; 57(1):113-23. PubMed ID: 17928397 [TBL] [Abstract][Full Text] [Related]
14. Mice lacking endogenous IL-10-producing regulatory B cells develop exacerbated disease and present with an increased frequency of Th1/Th17 but a decrease in regulatory T cells. Carter NA; Vasconcellos R; Rosser EC; Tulone C; Muñoz-Suano A; Kamanaka M; Ehrenstein MR; Flavell RA; Mauri C J Immunol; 2011 May; 186(10):5569-79. PubMed ID: 21464089 [TBL] [Abstract][Full Text] [Related]
15. Functional stability of Foxp3+ regulatory T cells. da Silva Martins M; Piccirillo CA Trends Mol Med; 2012 Aug; 18(8):454-62. PubMed ID: 22771168 [TBL] [Abstract][Full Text] [Related]